A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

PURPOSE: The phase I study characterized the safety, pharmacokinetics, anti-tumor activity, and recommended phase II dose/schedule of LY3164530 in patients with advanced or metastatic cancer. METHODS: Patients received LY3164530 on days 1 and 15 (Schedule 1: 300, 600, 1000, and 1250 mg) or Days 1, 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Patnaik, Amita, Gordon, Michael, Tsai, Frank, Papadopoulous, Kyri, Rasco, Drew, Beeram, S. Muralidhar, Fu, Siqing, Janku, Filip, Hynes, Scott M., Gundala, Sushma R., Willard, Melinda D., Zhang, Wei, Lin, Aimee Bence, Hong, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105165/
https://www.ncbi.nlm.nih.gov/pubmed/29926131
http://dx.doi.org/10.1007/s00280-018-3623-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105165/
https://www.ncbi.nlm.nih.gov/pubmed/29926131
http://dx.doi.org/10.1007/s00280-018-3623-7

Ejemplares similares